{
  "docId": "019de077-72f9-7549-be02-1cb8598bb783",
  "docSlug": "e2ad68eb257d4e7a3f142ed0c8be9c7f",
  "documentTitle": "AN2 Therapeutics | Investor Presentation Deck | 36 slides",
  "authorId": "an2-therapeutics",
  "authorName": "AN2 Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2025-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 36,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "LSM = Least squares mean. PRO = Patient-Reported Outcome. The slide highlights alignment with FDA guidance for primary endpoints in NTM trials.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-72f9-7549-be02-1cb8598bb783/11",
  "deckHref": "/decks/019de077-72f9-7549-be02-1cb8598bb783",
  "deckJsonHref": "/decks/019de077-72f9-7549-be02-1cb8598bb783.json",
  "deckAnchorHref": "/decks/019de077-72f9-7549-be02-1cb8598bb783#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.3,
        "x": 0.13,
        "y": 0.35
      },
      "kind": "list",
      "text": "FDA recommends primary endpoint of clinical effect, measured through PRO instrument",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0851ade6-23bc-4fb2-9bae-dfd4a3c57fbf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.3,
        "x": 0.13,
        "y": 0.55
      },
      "kind": "list",
      "text": "Insmed recently announced alignment with FDA to utilize QOL-B Respiratory continuous score and LSM analysis as primary endpoint in NTM (TN-MAC) confirmatory trial",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "be38da8f-0c78-4438-af8b-c1edb8a0c788",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.3,
        "x": 0.64,
        "y": 0.61
      },
      "kind": "metric",
      "text": "-5.8 points LSM change from baseline to month 6 (post-hoc) EBO+OBR vs. placebo+OBR P=0.043",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "02f26121-1d0f-45a0-9a2e-ceb8dfd5cf09",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.3,
        "x": 0.64,
        "y": 0.36
      },
      "kind": "metric",
      "text": "+6.9 points LSM change from baseline to month 6 (prespecified secondary) EBO+OBR vs. placebo+OBR P=0.036",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "86560ea9-54f9-4b16-8be2-f75862624bd1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.72,
        "x": 0.14,
        "y": 0.21
      },
      "kind": "paragraph",
      "text": "PRO outcomes from Phase 2 EBO-301 trial appear aligned with FDA Guidance",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "12110db5-4f81-4ca2-8db8-6abb97df19db",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.23,
        "y": 0.89
      },
      "kind": "source-note",
      "text": "LSM= Least squares mean. 1 Nontuberculous Mycobacterial Pulmonary Disease Caused by Mycobacterium avium Complex: Developing Drugs for Treatment, Guidance for Industry, September 2023. 2 Insmed Investor Presentation, October 2024. 3 Measures of patient improvement for QOL-B are shown by positive changes in the score measured from baseline. 4 Measures of patient improvement for MACro2 are shown by negative changes in the score measured from baseline.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "59d70d14-3003-48fd-9646-2a0711ee7a74",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.96,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "Clinical POC Achieved Across Two PROs in Toughest to Treat Patients",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aa38baef-1075-4327-9a94-c28343b47afc",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 14,
      "from": 9,
      "beatId": "cc73c19c-ae43-4e15-b621-ac27bebabaca",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "Phase 2 top-line results and clinical POC",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}